Skip to Content Facebook Feature Image

ExOne Global Holdings Unifies ExOne and voxeljet

News

ExOne Global Holdings Unifies ExOne and voxeljet
News

News

ExOne Global Holdings Unifies ExOne and voxeljet

2025-10-23 21:00 Last Updated At:21:10

GERSTHOFEN, Germany & FRIEDBERG, Germany & WASHINGTON--(BUSINESS WIRE)--Oct 23, 2025--

Anzu Partners, a U.S.-based industrial technology investment firm, today announces that ExOne Global Holdings has combined ExOne and voxeljet, two leaders in industrial additive manufacturing, under a unified holding structure. Going forward, the two businesses will integrate their operations to provide customers with a broader product line, deeper aftermarket support, and global printing services. ExOne Global Holdings will maintain the operating subsidiaries in Germany, the United States, Japan, China, and India that comprise the combined organization. These subsidiaries will continue and strengthen localized, regional support in all facets of the business.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022554126/en/

Under the new alignment:

This leadership structure is intended to blend deep domain expertise from both organizations while providing strong strategic oversight and continuity. The managing directors at each of the country organizations will remain the same.

“Our customers and partners will experience ongoing stability and consistency as we move forward,” said Eric Bader. “In bringing together ExOne’s leadership in digital sand casting and voxeljet’s capabilities in large-format industrial printing supporting sand and investment casting, our focus is to leverage our joined strengths, preserve reliability, and deliver new growth.”

“We are thrilled to bring together two of the most respected names in industrial binder-jet and large-format additive manufacturing,” said Whitney Haring-Smith. “ExOne and voxeljet each bring unique strengths and customer relationships. Under a single ownership and with unified leadership, we intend to accelerate innovation and deepen customer commitment.”

“I am honored to join the board of the new holding company,” said Rudolf Franz. “Both ExOne and voxeljet have set new standards for decades now by transforming casting applications through additive manufacturing. Reuniting the founders and pioneers of 3D sand printing is an exciting new step.”

By bringing these organizations together, Anzu is building a future-ready additive-manufacturing network designed for growth and resilience. Together, ExOne and voxeljet have deployed more than 500 industrial 3D printers with customers on every inhabited continent. The strategy leverages complementary technology portfolios, shared R&D, optimized operational 3d printing solutions, and cross-selling opportunities across both customer bases.

About Anzu Partners

Anzu Partners is an investment firm focused on clean-tech, industrial, and life-science technology companies with transformative potential. The firm partners with entrepreneurial teams to commercialize innovation through capital, strategic support, operational expertise, and global connectivity. As of 2024, Anzu Partners manages approximately $1 billion in assets.

Forward-Looking Statements

This press release contains forward-looking statements, including expectations regarding synergies, integration, growth, financial performance, and timing. These statements are subject to risks, uncertainties, and assumptions that could cause actual outcomes to differ materially. Neither Anzu Partners nor the companies make any guarantees about future performance.

Pictured (left to right): Rudolf Franz, Whitney Haring-Smith, Eric Bader.

Pictured (left to right): Rudolf Franz, Whitney Haring-Smith, Eric Bader.

SAN FRANCISCO--(BUSINESS WIRE)--Dec 15, 2025--

OrganaBio, LLC, a leading provider of human research- and clinical-grade cellular starting materials and clinical trial support services today announced the opening of its newest cell processing and cryopreservation facility in Hayward, California, further strengthening its nationwide network supporting cell therapy developers and clinical trial sponsors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215548505/en/

The new Bay Area site located at 25801 Industrial Boulevard, Hayward, CA 94545 expands OrganaBio’s reach to one of the most vibrant biotech and life science hubs in the world. Strategically located near major academic institutions, clinical research centers, and biotechnology innovators, the Hayward site will enable faster, more efficient support for Northern California clinical sites requiring time-sensitive processing of clinical trial samples.

This expansion enables sponsors to have cryopreserved samples within 3-4 hours of sample collection - a critical factor for maintaining cell viability and function.

OrganaBio offers industry-leading turnaround times and exceptional quality metrics, with an average PBMC viability of 99.1% and PBMC recovery exceeding 2.9 e6/mL. OrganaBio’s exceptional performance is driven by a rigorously trained team, qualified across multiple internal and Sponsor-specific SOPs. These operators continuously refine their technique by routinely isolating PBMCs from leukopaks and whole blood in support of its cellular starting material products business.

OrganaBio’s operators also travel between facilities to ensure consistency, reproducibility, and quality across all sites, a critical factor as clinical programs scale and expand geographically.

“Our rapid turnaround time, averaging just 76 minutes from blood draw to the start of cell isolation, is not just an impressive metric; it is a critical differentiator for data integrity. The opening of our second West Coast lab in Hayward is a direct investment in maintaining this operational speed and quality, ensuring that our clinical partners receive the most viable and functionally relevant cellular products, regardless of where their trial sites are located.” - Sarah Alter, Ph.D., Laboratory Director, OrganaBio.

With bi-coastal operations, OrganaBio continues to build on its mission to accelerate access to high-quality donor materials and manufacturing solutions, supporting the rapid development and delivery of next-generation therapies.

About OrganaBio, LLC

OrganaBio provides ethically sourced starting materials and clinical trial support services for advanced therapies. With facilities on both coasts, the company offers primary cells, leukopaks, birth tissue derivatives, and sample processing services, delivering fast turnaround, high quality, and consistency for biopharma partners.

OrganaBio opens up a new Peripheral Blood Mononuclear Cells (PBMC) processing lab in the Greater San Francisco area (Hayward, CA) to support rapid, time-sensitive isolation of PBMCs from clinical trial participant whole blood & leukopaks

OrganaBio opens up a new Peripheral Blood Mononuclear Cells (PBMC) processing lab in the Greater San Francisco area (Hayward, CA) to support rapid, time-sensitive isolation of PBMCs from clinical trial participant whole blood & leukopaks

Recommended Articles